Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal

Behavioural Pharmacology

Volumn 20, Issue 7, 2009, Pages 576-583

  Hofford, Rebecca S ^a   Hodgson, Stephen R ^a   Roberts, Kris W ^b   Bryant, Camron D ^c   Evans, Christopher J ^b   Eitan, Shoshana ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dependence; Mitogen activated protein kinase; Morphine,mouse; Naloxone; Opioid signaling

Indexed keywords

ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; NALOXONE;

AFFECT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVERSIVE BEHAVIOR; BEHAVIOR; CONTROLLED STUDY; EMOTION; ENZYME ACTIVATION; ENZYME INHIBITION; LIMBIC CORTEX; LOCUS CERULEUS; MALE; MAZE TEST; MORPHINE ADDICTION; MOUSE; NONHUMAN; SEPTUM PELLUCIDUM; WITHDRAWAL SYNDROME;

AMINOACETONITRILE; AMYGDALA; ANIMALS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MORPHINE; NALOXONE; SEPTUM OF BRAIN; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 70349671773     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832ec57e     Document Type: Article

References (51)

1. Aghajanian GK (1978). Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 276:186-188.
2. Aghajanian GK (1982). Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatr 43:20-24.
3. Almela P, Milané s MV, Laorden ML (2007). Activation of the ERK signaling pathway contributes to the adaptive changes in rat hearts during naloxoneinduced morphine withdrawal. Br J Pharmacol 151:787-797.
4. Asensio VJ, Miralles A, Garcia-Sevilla JA (2006). Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol 539:49-56.
5. Aston-Jones G, Delfs JM, Druhan J, Zhu Y (1999). The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Ann N Y Acad Sci 877:486-498.
6. Broseta I, Rodriguez-Arias M, Aguilar MA, Minarro J (2005). Isolation decreases physical and motivational aspects of morphine withdrawal. Behav Pharmacol 16:131-138.
7. Bryant CD, Zaki PA, Carroll FI, Evans CJ (2005). Opioids and addiction: Emerging pharmaceutical strategies for reducing reward and opponent processes. Clin Neurosci Res 5:103-115.
8. Buckman SG, Hodgson SR, Hofford RS, Eitan S (2009). Increased elevated plus maze open-arm time in mice during spontaneous morphine withdrawal. Behav Brain Res 197:454-456.
9. Cao JL, He JH, Ding HL, Zeng YM (2005). Activation of the spinal ERK signaling pathway contributes naloxone-precipitated withdrawal in morphine-dependent rats. Pain 118:336-349.
10. Cao JL, Liu HL,Wang JK, Zeng YM (2006). Cross talk between nitric oxide and ERK1/2 signaling pathway in the spinal cord mediates naloxone-precipitated withdrawal in morphine-dependent rats. Neuropharmacology 51:315-326.
11. Chieng B, Christie MJ (1995). Lesions to terminals of noradrenergic locus coeruleus neurones do not inhibit opiate withdrawal behaviour in rats. Neurosci Lett 186:37-40.
12. Chieng BC, Christie MJ, Osborne PB (2006). Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology, and opioid sensitivity. J Comp Neurol 497:910-927.
13. Crawley JN, Laverty R, Roth RH (1979). Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal. Eur J Pharmacol 57:247-250.
14. Cruz HG, Berton F, Sollini M, Blanchet C, Pravetoni M, Wickman K, Lüscher C (2008). Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. J Neurosci 28:4069-4077.
15. Eitan S, Bryant CD, Saliminejad N, Ansonoff M, Yang YC, Keith D, et al. (2002). Modulation of MAPK activation in vivo following acute opioid agonist or antagonist treatment. Society for Neuroscience, Orlando, Florida, poster number 643.2.
16. Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, Keith D Jr, et al. (2003). Brain region-specific mechanisms for acute morphine-induced mitogenactivated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci 23:8360-8369.
17. Engberg G, Elam M, Svensson TH (1982). Clonidine withdrawal: activation of brain noradrenergic neurons with specifically reduced alpha 2-receptor sensitivity. Life Sci 30:235-243.
18. Frenois F, Cador M, Caillé S, Stinus L, Le Moine C (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16:1377-1389.
19. Gestreau C, Le Guen S, Besson JM (2000). Is there tonic activity in the endogenous opioid systems? A c-Fos study in the rat central nervous system after intravenous injection of naloxone or naloxone-methiodide. J Comp Neurol 427:285-301.
20. Gracy KN, Dankiewicz LA, Koob GF (2001). Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24:152-160.
21. Hamlin AS, Buller KM, Day TA, Osborne PB (2004). Effect of naloxoneprecipitated morphine withdrawal on c-fos expression in rat corticotropinreleasing hormone neurons in the paraventricular hypothalamus and extended amygdala. Neurosci Lett 362:39-43.
22. Han MH, Bolaños CA, Green TA, Olson VG, Neve RL, Liu RJ, et al. (2006). Role of cAMP response element-binding protein in the rat locus ceruleus: regulation of neuronal activity and opiate withdrawal behaviors. J Neurosci 26:4624-4629.
23. Harris GC, Aston-Jones G (2007). Activation in extended amygdala corresponds to altered hedonic processing during protracted morphine withdrawal. Behav Brain Res 176:251-258.
24. Hodgson SR, Hofford RS, Norris CJ, Eitan S (2008). Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal. Behav Pharmacol 19:805-811.
25. Iorio LC, Deacon MA, Ryan EA (1975). Blockade by narcotic drugs of naloxone precipitated jumping in morphine-dependent mice. J Pharmacol Exp Ther 192:58-63.
26. Jin C, Araki H, Nagata M, Shimosaka R, Shibata K, Suemaru K, et al. (2005). Expression of c-Fos in the rat central amygdala accompanies the acquisition but not expression of conditioned place aversion induced by withdrawal from acute morphine dependence. Behav Brain Res 161:107-112.
27. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM (2007). Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein- competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346-355.
28. Koob GF, Caine SB, Parsons L, Markou A, Weiss F (1997). Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 57:513-521.
29. Lane-Ladd SB, Pineda J, Boundy VA, Pfeuffer T, Krupinski J, Aghajanian GK, Nestler EJ (1997). CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci 17:7890-7901.
30. Le Merrer J, Cagniard B, Cazala P (2006). Modulation of anxiety by mu-opioid receptors of the lateral septal region in mice. Pharmacol Biochem Behav 83:465-479.
31. Li Y-Q, Li F-Q, Wang X-Y, Wu P, Zhao M, Shaham Y, Lu L (2008). Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving. J Neurosci 28:13248-13257.
32. Maldonado C, Rodríguez-Arias M, Aguilar MA, Miñarro J (2004). GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice. Psychopharmacology (Berl) 177:130-140.
33. Maldonado R, Stinus L, Gold LH, Koob GF (1992). Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669-677.
34. Mansour A, Thompson RC, Akil H, Watson SJ (1993). Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanat 6:351-362.
35. Marchant NJ, Densmore VS, Osborne PB (2007). Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division. J Comp Neurol 504:702-715.
36. Mirzaii-Dizgah I, Karimian SM, Hajimashhadi Z, Riahi E, Ghasemi T (2008). Attenuation of morphine withdrawal signs by muscimol in the locus coeruleus of rats. Behav Pharmacol 19:171-175.
37. Nakagawa T, Satoh M (2004). Involvement of glial glutamate transporters in morphine dependence. Ann N Y Acad Sci 1025:383-388.
38. Nakagawa T, Yamamoto R, Fujio M, Suzuki Y, Minami M, Satoh M, Kaneko S (2005). Involvement of the bed nucleus of the stria terminalis activated by the central nucleus of the amygdala in the negative affective component of morphine withdrawal in rats. Neuroscience 134:9-19.
39. Oh KW, Eun JS, Kwon HN, Cho EY, Kim KM (2007). Effects of (-)- epigallocatechin gallate on the development of morphine-induced physical dependence. Arch Pharm Res 30:1111-1115.
40. Ozawa T, Nakagawa T, Sekiya Y, Minami M, Satoh M (2004). Effect of gene transfer of GLT-1, a glutamate transporter, into the locus coeruleus by recombinant adenoviruses on morphine physical dependence in rats. Eur J Neurosci 19:221-226.
41. Paxinos G, Franklin KBJ (2001). The Mouse Brain in Stereotaxic Coordinates, second edition. San Diego, CA: Academic Press.
42. Poulin JF, Castonguay-Lebel Z, Laforest S, Drolet G (2008). Enkephalin co-expression with classic neurotransmitters in the amygdaloid complex of the rat. J Comp Neurol 506:943-959.
43. Schulteis G, Koob GF (1996). Reinforcement processes in opiate addiction: a homeostatic model. Neurochem Res 21:1437-1454.
44. Schulz S, Hollt V (1998). Opioid withdrawal activates MAP kinase in locus coeruleus neurons in morphine-dependent rats in vivo. Eur J Neurosci 10:1196-1201.
45. Shoblock JR, Maidment NT (2006). Constitutively active mu opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphinedependent mice. Neuropsychopharmacology 31:171-177.
46. Skoubis PD, Lam HA, Shoblock J, Narayanan S, Maidment NT (2005). Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci 21:1379-1384.
47. Valverde O, Mantamadiotis T, Torrecilla M, Ugedo L, Pineda J, Bleckmann S, et al. (2004). Modulation of anxiety-like behavior and morphine dependence in CREB-deficient mice. Neuropsychopharmacology 29:1122-1133.
48. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M (2002). Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Jpn J Pharmacol 88:399-406. (Pubitemid 34516565)
49. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M (2003). Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology (Berl) 170:80-88.
50. Veinante P, Stoeckel ME, Lasbennes F, Freund-Mercier MJ (2003). c-Fos and peptide immunoreactivities in the central extended amygdala of morphinedependent rats after naloxone-precipitated withdrawal. Eur J Neurosci 18:1295-1305.
51. Zachariou V, Liu R, LaPlant Q, Xiao G, Renthal W, Chan GC, et al. (2008). Distinct roles of adenylyl cyclases 1 and 8 in opiate dependence: behavioral, electrophysiological, and molecular studies. Biol Psychiatr 63:1013-1021.